Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia
Status:
Recruiting
Trial end date:
2025-05-12
Target enrollment:
Participant gender:
Summary
A randomized, open-label, multicenter study to compare the efficacy and safety of
teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy
for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia
(ITP).
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Beijing Friendship Hospital Beijing Hospital Beijing Luhe Hospital Beijing Tsinghua Changgeng Hospital China-Japan Friendship Hospital Chinese PLA General Hospital Navy General Hospital, Beijing Peking University First Hospital Peking University Third Hospital